Verrica Pharmaceuticals Inc. (VRCA)
| Market Cap | 75.24M +84.9% |
| Revenue (ttm) | 30.32M +106.2% |
| Net Income | -31.18M |
| EPS | -1.88 |
| Shares Out | 17.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 44,712 |
| Open | 4.560 |
| Previous Close | 4.515 |
| Day's Range | 4.370 - 4.843 |
| 52-Week Range | 3.280 - 9.821 |
| Beta | 1.61 |
| Analysts | Strong Buy |
| Price Target | 13.83 (+215.75%) |
| Est. Earnings | Nov 13, 2026 |
About VRCA
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of... [Read more]
Financial Performance
In 2025, Verrica Pharmaceuticals's revenue was $35.58 million, an increase of 370.22% compared to the previous year's $7.57 million. Losses were -$17.89 million, -76.64% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for VRCA stock is "Strong Buy." The 12-month stock price target is $13.83, which is an increase of 215.75% from the latest price.
News
Verrica Pharmaceuticals to present new YCANTH data at upcoming conferences
Verrica Pharmaceuticals (VRCA) announced that it will present posters on a new analysis of Phase 3 trials of YCANTH and an encore presentation of data from a Phase 2 trial…
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration –
Verrica Pharmaceuticals management to meet virtually with Lake Street
Virtual Meeting to be held on September 30 hosted by Lake Street.
Verrica Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Significant progress was highlighted in commercializing YCANTH for molluscum and advancing global phase III trials for common warts, with strong efficacy and safety data. VP-315 for basal cell carcinoma is phase III-ready, showing high response rates and expedited regulatory pathways.
Verrica Pharmaceuticals Slides: Corporate presentation
Verrica Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2026.
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
– Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration –
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
WEST CHESTER, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of de...
Lake Street starts Verrica Pharmaceuticals with a Buy
As previously reported, Lake Street initiated coverage of Verrica Pharmaceuticals (VRCA) with a Buy rating and $9 price target Following behind YCANTH in molluscum contagiosum is an ongoing global Pha...
Verrica Pharmaceuticals initiated with a Buy at Lake Street
Lake Street initiated coverage of Verrica Pharmaceuticals (VRCA) with a Buy rating and $9 price target
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
– Per-protocol interim statistical power analysis confirms no additional patients are recommended for full enrollment – – Second pivotal Phase 3 trial (COVE-3) has already exceeded 50% of current targ...
Verrica Pharmaceuticals CEO buys $125.8K in common stock
In a regulatory filing, Verrica Pharmaceuticals (VRCA) disclosed that its CEO Jayson Rieger bought 25K shares of common stock on August 14th in a total transaction size of $125.8K. Shares…
Verrica Pharmaceuticals reports Q2 EPS (62c), consensus (47c)
Reports Q2 revenue $5.86M, consensus $5.74M. “Demand for YCANTH continues to accelerate, with dispensed applicator units reaching 19,626 for the quarter, up approximately 28% sequentially and 46% on a...
Verrica Pharmaceuticals Earnings Call Transcript: Q2 2026
YCANTH achieved strong sequential growth in both revenue and units, supported by improved prescriber targeting and patient access. A new $27.5 million credit facility extends cash runway into 2028, while pivotal trials for common warts and VP-315 in basal cell carcinoma advance on schedule.
Verrica Pharmaceuticals Earnings release: Q2 2026
Verrica Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Verrica Pharmaceuticals Quarterly report: Q2 2026
Verrica Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.
Verrica Pharmaceuticals Slides: Corporate presentation
Verrica Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the...
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of der...
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan –
Verrica Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
YCANTH has seen improved access and growing adoption, with Q1 revenue at $4.3 million and over 100,000 applicator units dispensed. The pipeline includes a phase III common warts program (50% enrolled) and a BCC program with strong phase II results. Cash runway extends into Q1 2027.
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of derm...
Verrica Pharmaceuticals assumed with a Buy at H.C. Wainwright
H.C. Wainwright assumed coverage of Verrica Pharmaceuticals (VRCA) with a Buy rating and $12 price target The company reported “encouraging” Ycanth volume in Q1, the analyst tells investors in a…
Verrica Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
YCANTH has achieved strong commercial growth with expanding market penetration and robust support programs. International expansion is progressing, and the pipeline includes a large common warts program and a promising basal cell carcinoma candidate, VP-315, with significant clinical and commercial potential.
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of derm...
Verrica Pharmaceuticals reports Q1 adjusted EPS (41c), consensus (59c)
Reports Q1 revenue $5.02M, consensus $4.52M. “Our first quarter performance reflects accelerating growth in market demand for YCANTH as the new standard of care for the treatment of molluscum contagio...